Metabool syndroom bij de behandeling met clozapine
Abstract Metabolic syndrome during clozapine treatment Objective: To assess the prevalence of metabolic syndrome in inpatients with psychotic disorders treated with clozapine for at least one year. Design: Chronically admitted patients were screened on the use of clozapine and the presence of metabolic side effects. Methods: The Third Adult Treatment Panel was used tot assess metabolic syndrome. In addition, patient variables, dosage and plasma concentration of clozapine were recorded. Results: Included were 62 patients with a most prevalent diagnosis of schizophrenia. Mean duration of treatment with clozapine was 9.2 years. Metabolic syndrome was present in 60% of the patients and more frequent in cases with comedication of mood stabilizers. Conclusion: Metabolic syndrome is highly prevalent among patients treated with clozapine for psychotic disorders. Additional factors in the emergence of metabolic syndrome are: unhealthy life style, inactivity and comedication.
|Keywords||antipsychotica, clozapine, metabool syndroom|
Steylen, P.M.J., van der Heijden, F.M.M.A., Verhoeven, W.M.A., Kok, J.D.H., van Soest, M., & Tuinier, S.. (2009). Metabool syndroom bij de behandeling met clozapine. Pharmaceutisch Weekblad, 144(3), 96–100. Retrieved from http://hdl.handle.net/1765/22888